Lipid nanoparticles (SLN, NLC): Overcoming the anatomical and physiological barriers of the eye – Part II - Ocular drug-loaded lipid nanoparticles

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 110, Issue , 2017, Pages 58-69

  Sanchez Lopez E ^a   Espina, M ^a   Doktorovova, S ^b   Souto, E B ^b   Garcia M L ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Anterior chamber; Lipid nanoparticles; Ocular drug delivery; Posterior chamber; Vitreous humor

Indexed keywords

AGENTS ACTING ON THE EYE; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIVIRUS AGENT; CORTICOSTEROID; DRUG CARRIER; IMMUNOSUPPRESSIVE AGENT; LIPOSOME; NANOSTRUCTURED LIPID CARRIER; NONSTEROID ANTIINFLAMMATORY AGENT; SOLID LIPID NANOPARTICLE; SURFACTANT; UNCLASSIFIED DRUG; ACICLOVIR; ANTIINFECTIVE AGENT; COLLOID; EXCIPIENT; LIPID; METAL NANOPARTICLE; NANOPARTICLE; POLYMER; TRIACYLGLYCEROL;

AGE RELATED MACULAR DEGENERATION; ANATOMICAL CONCEPTS; ARTICLE; BLOOD EYE BARRIER; CATARACT; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; EYE DISEASE; EYE INFECTION; EYE INFLAMMATION; EYE TISSUE; GENE THERAPY; GLAUCOMA; HUMAN; OCULAR DRUG DELIVERY SYSTEM; BIOAVAILABILITY; CHEMISTRY; COLLOID; DRUG EFFECTS; DRUG STABILITY; EYE; EYE INFECTIONS; MACULAR DEGENERATION; PROCEDURES; SOLUBILITY; VITREOUS BODY;

ACYCLOVIR; ADRENAL CORTEX HORMONES; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIFUNGAL AGENTS; ANTIVIRAL AGENTS; BIOLOGICAL AVAILABILITY; COLLOIDS; DRUG CARRIERS; DRUG STABILITY; EXCIPIENTS; EYE; EYE INFECTIONS; GENETIC THERAPY; GLAUCOMA; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIPIDS; LIPOSOMES; MACULAR DEGENERATION; METAL NANOPARTICLES; NANOPARTICLES; POLYMERS; SOLUBILITY; SURFACE-ACTIVE AGENTS; TRIGLYCERIDES; VITREOUS BODY;

EID: 85002996216     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2016.10.013     Document Type: Article

References (96)

1. [1] Hwang, T.L., Aljuffali, I.A., Lin, C.F., Chang, Y.T., Fang, J.Y., Cationic additives in nanosystems activate cytotoxicity and inflammatory response of human neutrophils: lipid nanoparticles versus polymeric nanoparticles. Int. J. Nanomed. 10 (2015), 371–385, 10.2147/IJN.S73017.
2. [2] Li, N., Zhuang, C., Wang, M., Sun, X., Nie, S., Pan, W., Liposome coated with low molecular weight Chitosan and its potential use in ocular drug delivery. Int. J. Pharm. 379 (2009), 131–138, 10.1016/j.ijpharm.2009.06.020.
3. [3] Abdelkader, H., Ismail, S., Amal, K., Alan, R.G., Design and evaluation of controlled-release niosomes and discomes for naltrexone hydrochloride ocular delivery. J. Pharm. Sci. 100 (2011), 1833–1846, 10.1002/jps.
4. [4] Souto, E.B., Mehnert, W., Müller, R.H., Polymorphic behaviour of Compritol888 ATO as bulk lipid and as SLN and NLC. J. Microencapsul. 23 (2006), 417–433, 10.1080/02652040600612439.
5. [5] Souto, E.B., Müller, R.H., Investigation of the factors influencing the incorporation of clotrimazole in SLN and NLC prepared by hot high-pressure homogenization. J. Microencapsul. 23 (2006), 377–388, 10.1080/02652040500435295.
6. [6] Müller, R.H., Radtke, M., Wissing, S.A., Nanostructured lipid matrices for improved microencapsulation of drugs. Int. J. Pharm. 242 (2002), 121–128, 10.1016/S0378-5173(02)00180-1.
7. [7] Müller, R.H., Mader, K., Gohla, S., Solid lipid nanoparticles (SLN) for controlled drug delivery – a review of the state of the art. Eur. J. Pharm. Biopharm. 50 (2000), 161–177, 10.1016/S0939-6411(00)00087-4.
8. [8] Müller, R.H., Shegokar, R., Keck, C.M., 20 years of lipid nanoparticles (SLN and NLC): present state of development and industrial applications. Curr. Drug Discov. Technol. 8 (2011), 207–227, 10.2174/157016311796799062.
9. [9] Doktorovova, S., Souto, E.B., Silva, A.M., Nanotoxicology applied to solid lipid nanoparticles and nanostructured lipid carriers – a systematic review of in vitro data. Eur. J. Pharm. Biopharm. 87 (2014), 1–18, 10.1016/j.ejpb.2014.02.005.
10. [10] Beloqui, A., Solinís, M.A., Rodríguez-Gascón, A., Almeida, A.J., Préat, V., Nanostructured lipid carriers: promising drug delivery systems for future clinics. Nanomedicine 12 (2016), 143–161, 10.1016/j.nano.2015.09.004.
11. [11] Mehnert, W., Solid lipid nanoparticles Production, characterization and applications. Adv. Drug Deliv. Rev. 47 (2001), 165–196, 10.1016/S0169-409X(01)00105-3.
12. [12] Shen, J., Sun, M., Ping, Q., Ying, Z., Liu, W., Incorporation of liquid lipid in lipid nanoparticles for ocular drug delivery enhancement. Nanotechnology, 21, 2010, 025101, 10.1088/0957-4484/21/2/025101.
13. [13] Seyfoddin, A., Shaw, J., Al-Kassas, R., Solid lipid nanoparticles for ocular drug delivery. Drug Deliv. 17 (2010), 467–489, 10.3109/10717544.2010.483257.
14. [14] M.R. Gasco, G.P. Zara, M.F. Saettone, Pharmaceutical Compositions Suitable for the Treatment of Ophthalmic Diseases, WO/2004/039351, 2004.
15. [15] Cortesi, R., Argnani, R., Esposito, E., Dalpiaz, A., Scatturin, A., Bortolotti, F., et al. Cationic liposomes as potential carriers for ocular administration of peptides with anti-herpetic activity. Int. J. Pharm. 317 (2006), 90–100, 10.1016/j.ijpharm.2006.02.050.
16. [16] Fangueiro, J.F., Andreani, T., Egea, M.A., Garcia, M.L., Souto, S.B., Silva, A.M., et al. Design of cationic lipid nanoparticles for ocular delivery: development, characterization and cytotoxicity. Int. J. Pharm. 461 (2014), 64–73, 10.1016/j.ijpharm.2013.11.025.
17. [17] del Pozo-Rodríguez, A., Delgado, D., Gascón, A.R., Solinís, M.Á., Lipid nanoparticles as drug/gene delivery systems to the retina. J. Ocul. Pharmacol. Ther. 29 (2013), 173–188, 10.1089/jop.2012.0128.
18. [18] Souto, E.B., Doktorovova, S., Gonzalez-Mira, E., Egea, M.A., Garcia, M.L., Feasibility of lipid nanoparticles for ocular delivery of anti-inflammatory drugs. Curr. Eye Res. 35 (2010), 537–552, 10.3109/02713681003760168.
19. [19] Leonardi, A., Bucolo, C., Romano, G.L., Platania, C.B.M., Drago, F., Puglisi, G., et al. Influence of different surfactants on the technological properties and in vivo ocular tolerability of lipid nanoparticles. Int. J. Pharm. 470 (2014), 133–140, 10.1016/j.ijpharm.2014.04.061.
20. [20] Okur, N.Ü., Gökçe, E.H., Lipid nanoparticles for ocular drug delivery. Int. J. Ophthal. Res. 1 (2015), 77–82, 10.17554/j.issn.2409-5680.2015.01.29.
21. [21] Jabs, D.A., Treatment of ocular inflammation. Ocul. Immunol. Inflamm. 12 (2004), 163–168, 10.1080/09273940490883671.
22. [22] Araújo, J., Gonzalez-Mira, E., Egea, M.A., Garcia, M.L., Souto, E.B., Optimization and physicochemical characterization of a triamcinolone acetonide-loaded NLC for ocular antiangiogenic applications. Int. J. Pharm. 393 (2010), 168–176, 10.1016/j.ijpharm.2010.03.034.
23. [23] Araújo, J., Garcia, M.L., Mallandrich, M., Souto, E.B., Calpena, A.C., Release profile and transscleral permeation of triamcinolone acetonide loaded nanostructured lipid carriers (TA-NLC): in vitro and ex vivo studies. Nanomed. Nanotechnol., Biol. Med. 8 (2012), 1034–1041, 10.1016/j.nano.2011.10.015.
24. [24] Araújo, J., Nikolic, S., Egea, M.A., Souto, E.B., Garcia, M.L., Nanostructured lipid carriers for triamcinolone acetonide delivery to the posterior segment of the eye. Colloids Surf. B Biointerf. 88 (2011), 150–157, 10.1016/j.colsurfb.2011.06.025.
25. [25] Ahuja, M., Dhake, A.S., Sharma, S.K., Majumdar, D.K., Topical ocular delivery of NSAIDs. AAPS J. 10 (2008), 229–241, 10.1208/s12248-008-9024-9.
26. [26] Gaynes, B.I., Fiscella, R., Topical nonsteroidal anti-inflammatory drugs for ophthalmic use: a safety review. Drug Saf. 25 (2002), 233–250, 10.2165/00002018-200225040-00002.
27. [27] Sashmal, S., Mukherjee, S., Ray, S., Thakur, R., Ghosh, L., Gupta, B., Design and optimization of NSAID loaded nanoparticles. Pak. J. Pharm. Sci. 20 (2007), 157–162.
28. [28] Vega, E., Egea, M., Valls, O., Espina, M., García, M., Flurbiprofen loaded biodegradable nanoparticles for ophtalmic administration. J. Pharm. Sci. 95 (2006), 2393–2405, 10.1002/jps.
29. [29] Abrego, G., Alvarado, H.L., Egea, M.A., Gonzalez-Mira, E., Calpena, A.C., Garcia, M.L., Design of nanosuspensions and freeze-dried PLGA nanoparticles as a novel approach for ophthalmic delivery of pranoprofen. J. Pharm. Sci. 103 (2014), 3153–3164, 10.1002/jps.24101.
30. [30] Vasconcelos, A., Vega, E., Pérez, Y., Gomara, M.J., García, M.L., Haro, I., Conjugation of cell-penetrating peptides with poly (lactic-co-glycolic acid) -polyethylene glycol nanoparticles improves ocular drug delivery. Int. J. Nanomed. 10 (2015), 609–631, 10.2147/IJN.S71198.
31. [31] Attama, A.A., Reichl, S., Müller-Goymann, C.C., Diclofenac sodium delivery to the eye: In vitro evaluation of novel solid lipid nanoparticle formulation using human cornea construct. Int. J. Pharm. 355 (2008), 307–313, 10.1016/j.ijpharm.2007.12.007.
32. [32] Li, X., Nie, S.F., Kong, J., Li, N., yi Ju, C., san Pan, W., A controlled-release ocular delivery system for ibuprofen based on nanostructured lipid carriers. Int. J. Pharm. 363 (2008), 177–182, 10.1016/j.ijpharm.2008.07.017.
33. [33] Gonzalez-Mira, E., Egea, M.A., Garcia, M.L., Souto, E.B., Design and ocular tolerance of flurbiprofen loaded ultrasound-engineered NLC. Colloids Surf. B Biointerf. 81 (2010), 412–421, 10.1016/j.colsurfb.2010.07.029.
34. [34] Gonzalez-Mira, E., Egea, M.A., Souto, E.B., Calpena, A., García, M.L., Optimizing flurbiprofen-loaded NLC by central composite factorial design for ocular delivery. Nanotechnology, 22, 2011, 045101, 10.1088/0957-4484/22/4/045101.
35. [35] González-Mira, E., Nikolic, S., Calpena, A., Egea, M., Souto, E., García, M., Improved and safe transcorneal delivery of Flurbiprofen by NLC and NLC-based hydrogels. J. Pharm. Sci. 101 (2012), 707–725, 10.1002/jps.22784.
36. [36] Luo, Q., Zhao, J., Zhang, X., Pan, W., Nanostructured lipid carrier (NLC) coated with Chitosan Oligosaccharides and its potential use in ocular drug delivery system. Int. J. Pharm. 403 (2011), 185–191, 10.1016/j.ijpharm.2010.10.013.
37. [37] Hippalgaonkar, K., Adelli, G.R., Hippalgaonkar, K., Repka, M.A., Majumdar, S., Indomethacin-loaded solid lipid nanoparticles for ocular delivery: development, characterization, and in vitro evaluation. J. Ocul. Pharmacol. Ther. 29 (2013), 216–228, 10.1089/jop.2012.0069.
38. [38] Jabs, D., Rosenbaum, J., Foster, C., Holland, G., Jaffe, G., Louie, J., et al. Guidelines for the use of Immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am. J. Ophthalmol. 130 (2000), 492–513, 10.1016/S0002-9394(01)00830-3.
39. [39] Kuwano, M., Ibuki, H., Morikawa, N., Ota, A., Kawashima, Y., Cyclosporine A formulation affects its ocular distribution in rabbits. Pharm. Res. 19 (2002), 108–111.
40. [40] Başaran, E., Demirel, M., Sirmagül, B., Yazan, Y., Cyclosporine-A incorporated cationic solid lipid nanoparticles for ocular delivery. J. Microencapsul. 27 (2010), 37–47, 10.3109/02652040902846883.
41. [41] Lallemand, F., Felt-Baeyens, O., Besseghir, K., Behar-Cohen, F., Gurny, R., Cyclosporine A delivery to the eye: a pharmaceutical challenge. Eur. J. Pharm. Biopharm. 56 (2003), 307–318, 10.1016/S0939-6411(03)00138-3.
42. [42] Ugazio, E., Cavalli, R., Gasco, M.R., Incorporation of cyclosporin A in solid lipid nanoparticles (SLN). Int. J. Pharm. 241 (2002), 341–344.
43. [43] Müller, R.H., Runge, S.A., Ravelli, V., Tünemann, A.F., Mehnert, W., Souto, E.B., Cyclosporine-loaded solid lipid nanoparticles (SLN): drug-lipid physicochemical interactions and characterization of drug incorporation. Eur. J. Pharm. Biopharm. 68 (2008), 535–544, 10.1016/j.ejpb.2007.07.006.
44. [44] Gokce, E.H., Sandri, G., Bonferoni, M.C., Rossi, S., Ferrari, F., Güneri, T., et al. Cyclosporine A loaded SLNs: evaluation of cellular uptake and corneal cytotoxicity. Int. J. Pharm. 364 (2008), 76–86, 10.1016/j.ijpharm.2008.07.028.
45. [45] Gökçe, E.H., Sandri, G., Eğrilmez, S., Bonferoni, M.C., Güneri, T., Caramella, C., Cyclosporine A-loaded solid lipid nanoparticles: ocular tolerance and in vivo drug release in rabbit eyes. Curr. Eye Res. 34 (2009), 996–1003, 10.3109/02713680903261405.
46. [46] Sandri, G., Bonferoni, M.C., Gökçe, E.H., Ferrari, F., Rossi, S., Patrini, M., et al. Chitosan-associated SLN: in vitro and ex vivo characterization of cyclosporine A loaded ophthalmic systems. J. Microencapsul. 27 (2010), 735–746, 10.3109/02652048.2010.517854.
47. [47] Battaglia, L., D'Addino, I., Peira, E., Trotta, M., Gallarate, M., Solid lipid nanoparticles prepared by coacervation method as vehicles for ocular cyclosporine. J. Drug Deliv. Sci. Technol. 22 (2012), 125–130, 10.1016/S1773-2247(12)50016-X.
48. [48] Bertino, J.S., Impact of antibiotic resistance in the management of ocular infections: the role of current and future antibiotics. Clin. Ophthalmol. 3 (2009), 507–521, 10.2147/OPTH.S5778.
49. [49] Bourcier, T., Thomas, F., Borderie, V., Chaumeil, C., Laroche, L., Bacterial keratitis: predisposing factors, clinical and microbiological review of 300 cases. Br. J. Ophthalmol. 87 (2003), 834–838, 10.1136/bjo.87.7.834.
50. [50] Cavalli, R., Bargoni, A., Podio, V., Muntoni, E., Zara, G.P., Gasco, M.R., Duodenal administration of solid lipid nanoparticles loaded with different percentages of tobramycin. J. Pharm. Sci. 92 (2003), 1085–1094, 10.1002/jps.10368.
51. [51] Cavalli, R., Gasco, M.R., Chetoni, P., Burgalassi, S., Saettone, M.F., Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin. Int. J. Pharm. 238 (2002), 241–245, 10.1016/S0378-5173(02)00080-7.
52. [52] Hao, J., Fang, X., Zhou, Y., Wang, J., Guo, F., Li, F., et al. Development and optimization of solid lipid nanoparticle formulation for ophthalmic delivery of chloramphenicol using a Box-Behnken design. Int. J. Nanomed. 6 (2011), 683–692, 10.2147/IJN.S17386.
53. [53] Wu, J.Y., Xia, Q., Preparation and characterization of Azithromycin-loaded nanostructured lipid carriers. Adv. Mater. Res. 236–238 (2011), 2917–2920.
54. [54] Blondeau, J.M., Fluoroquinolones: mechanism of action, classification, and development of resistance. Surv. Ophthalmol. 49 (2004), 1–6, 10.1016/j.survophthal.2004.01.005.
55. [55] Üstündaǧ-Okur, N., Gökçe, E.H., Bozbiyik, D.I., Eǧrilmez, S., Özer, Ö., Ertan, G., Preparation and in vitro-in vivo evaluation of ofloxacin loaded ophthalmic nano structured lipid carriers modified with chitosan oligosaccharide lactate for the treatment of bacterial keratitis. Eur. J. Pharm. Sci. 63 (2014), 204–215, 10.1016/j.ejps.2014.07.013.
56. [56] Baig, M.S., Ahad, A., Aslam, M., Imam, S.S., Aqil, M., Ali, A., Application of Box-Behnken design for preparation of levofloxacin-loaded stearic acid solid lipid nanoparticles for ocular delivery: optimization, in vitro release, ocular tolerance, and antibacterial activity. Int. J. Biol. Macromol. 85 (2016), 258–270, 10.1016/j.ijbiomac.2015.12.077.
57. [57] Kalam, M.A., Sultana, Y., Ali, A., Aqil, M., Mishra, A.K., Chuttani, K., Preparation, characterization, and evaluation of Gatifloxacin loaded solid lipid nanoparticles as colloidal ocular drug delivery system. J. Drug Target. 18 (2010), 191–204, 10.3109/10611860903338462.
58. [58] Kalam, M.A., Sultana, Y., Ali, A., Aqil, M., Mishra, A.K., Aljuffali, I.A., et al. Part I: Development and optimization of solid-lipid nanoparticles using Box-Behnken statistical design for ocular delivery of gatifloxacin. J. Biomed. Mater. Res. - Part A 101 A (2013), 1813–1827, 10.1002/jbm.a.34453.
59. [59] Kalam, A.M., Sultana, Y., Ali, A., Aqil, M., Mishra, A.K., Chuttani, K., et al. Part II: Enhancement of transcorneal delivery of gatifloxacin by solid lipid nanoparticles in comparison to commercial aqueous eye drops. J. Biomed. Mater. Res. - Part A 101 A (2013), 1828–1836, 10.1002/jbm.a.34467.
60. [60] Üner, M., Yener, G., Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspective. Int. J. Nanomed. 2 (2007), 289–300.
61. [61] Law, S.L., Huang, K.J., Chiang, C.H., Acyclovir-containing liposomes for potential ocular delivery Corneal penetration and absorption. J. Control. Release. 63 (2000), 135–140, 10.1016/S0168-3659(99)00192-3.
62. [62] Cortesi, R., Esposito, E., Acyclovir delivery systems. Expert Opin. Drug Deliv. 5247 (2008), 1217–1230, 10.1517/17425240802450340.
63. [63] Seyfoddin, A., Al-Kassas, R., Development of solid lipid nanoparticles and nanostructured lipid carriers for improving ocular delivery of acyclovir. Drug Dev. Ind. Pharm. 39 (2013), 1–12, 10.3109/03639045.2012.665460.
64. [64] Manzouri, B., Vafidis, G.C., Wyse, R.K., Pharmacotherapy of fungal eye infections. Expert Opin. Pharmacother. 2 (2001), 1849–1857, 10.1517/14656566.2.11.1849.
65. [65] Kakkar, S., Karuppayil, S.M., Raut, J.S., Giansanti, F., Papucci, L., Schiavone, N., et al. Lipid-polyethylene glycol based nano-ocular formulation of ketoconazole. Int. J. Pharm. 495 (2015), 276–289, 10.1016/j.ijpharm.2015.08.088.
66. [66] Mohanty, B., Majumdar, D.K., Mishra, S.K., Panda, A.K., Patnaik, S., Development and characterization of itraconazole-loaded solid lipid nanoparticles for ocular delivery. Pharm. Dev. Technol. 20 (2015), 458–464, 10.3109/10837450.2014.882935.
67. [67] J.H. Gurwitz, R.J. Glynn, M. Monane, D.E. Eveitt, D. Gilden, N. Smith, Treatment for Glaucoma : Adherence by the Elderly, 1992.
68. [68] Olthoff, C.M., Schouten, J.S., Van De Borne, B.W., Webers, C.A., Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension: an evidence-based review. Ophthalmology 112 (2005), 953–961, 10.1016/j.ophtha.2004.12.035.
69. [69] Cavalli, R., Morel, S., Gasco, M.R., Chetoni, P., Saettone, M.F., Preparation and evaluation in vitro of colloidal lipospheres containing pilocarpine as ion pair. Int. J. Pharm. 117 (1995), 243–246, 10.1016/0378-5173(94)00339-7.
70. [70] Lütfi, G., Müzeyyen, D., Preparation and characterization of polymeric and lipid nanoparticles of pilocarpine HCl for ocular application. Pharm. Dev. Technol. 18 (2013), 701–709, 10.3109/10837450.2012.705298.
71. [71] Attama, A., Reichl, S., Müller-Goymann, C., Sustained release and permeation of timolol from surface-modified solid lipid nanoparticles through bioengineered human cornea. Curr. Eye Res. 34 (2009), 698–705, 10.1080/02713680903017500.
72. [72] Kunal, J., Kumar, R., Sood, S., Dhyanandhan, G., Betaxolol Hydrochloride loaded Chitosan nanoparticles for ocular delivery and their antiglaucoma efficacy. Curr. Drug Deliv. 10 (2013), 493–499.
73. [73] Hou, D., Hu, S., Huang, Y., Gui, R., Zhang, L., Tao, Q., et al. Preparation and in vitro study of lipid nanoparticles encapsulating drug loaded montmorillonite for ocular delivery. Appl. Clay Sci. 119 (2016), 277–283, 10.1016/j.clay.2015.10.028.
74. [74] Li, R., Jiang, S., Liu, D., Bi, X., Wang, F., Zhang, Q., et al. A potential new therapeutic system for glaucoma: solid lipid nanoparticles containing methazolamide. J. Microencapsul. 28 (2011), 134–141, 10.3109/02652048.2010.539304.
75. [75] Jiang, S., Wang, F., Zhu, S., Zhang, X., Guo, Z., Li, R., et al. Preformulation study of methazolamide for topical ophthalmic delivery: physicochemical properties and degradation kinetics in aqueous solutions. Int. J. Pharm. 448 (2013), 390–393, 10.1016/j.ijpharm.2013.03.018.
76. [76] Wang, F., Chen, L., Jiang, S., He, J., Zhang, X., Peng, J., et al. Optimization of methazolamide-loaded solid lipid nanoparticles for ophthalmic delivery using Box-Behnken design. J. Liposome Res. 24 (2014), 171–181, 10.3109/08982104.2014.891231.
77. [77] Wang, F., Chen, L., Zhang, D., Jiang, S., Shi, K., Huang, Y., et al. Methazolamide-loaded solid lipid nanoparticles modified with low-molecular weight chitosan for the treatment of glaucoma: vitro and vivo study. J. Drug Target. 22 (2014), 849–858, 10.3109/1061186X.2014.939983.
78. [78] Youshia, J., Kamel, A.O., El Shamy, A., Mansour, S., Design of cationic nanostructured heterolipid matrices for ocular delivery of methazolamide. Int. J. Nanomed. 7 (2012), 2483–2496, 10.2147/IJN.S28307.
79. [79] Lundmark, P.O., Pandi-Perumal, S.R., Srinivasan, V., Cardinali, D.P., Rosenstein, R.E., Melatonin in the eye: implications for glaucoma. Exp. Eye Res. 84 (2007), 1021–1030, 10.1016/j.exer.2006.10.018.
80. [80] Alcantara-Contreras, S., Baba, K., Tosini, G., Removal of melatonin receptor type 1 increases intraocular pressure and retinal ganglion cells death in the mouse. Neurosci. Lett. 494 (2011), 61–64, 10.1016/j.neulet.2011.02.056.
81. [81] Leonardi, A., Bucolo, C., Drago, F., Salomone, S., Pignatello, R., Cationic solid lipid nanoparticles enhance ocular hypotensive effect of melatonin in rabbit. Int. J. Pharm. 478 (2015), 180–186, 10.1016/j.ijpharm.2014.11.032.
82. [82] Puglia, C., Offerta, A., Carbone, C., Bonina, F., Pignatelo, R., Puglisi, G., Lipid nanocarriers (LNC) and their applications in ocular drug delivery. Curr. Med. Chem. 22 (2015), 1589–1602.
83. [83] Fangueiro, J.F., Andreani, T., Fernandes, L., Garcia, M.L., Egea, M.A., Silva, A.M., et al. Physicochemical characterization of epigallocatechin gallate lipid nanoparticles (EGCG-LNs) for ocular instillation. Colloids Surf. B Biointerf. 123 (2014), 452–460, 10.1016/j.colsurfb.2014.09.042.
84. [84] Li, J., Guo, X., Liu, Z., Okeke, C.I., Li, N., Zhao, H., et al. Preparation and evaluation of charged solid lipid nanoparticles of tetrandrine for ocular drug delivery system: pharmacokinetics, cytotoxicity and cellular uptake studies. Drug Dev. Ind. Pharm. 40 (2014), 980–987, 10.3109/03639045.2013.795582.
85. [85] Liu, Z., Zhang, X., Wu, H., Li, J., Shu, L., Liu, R., et al. Preparation and evaluation of solid lipid nanoparticles of baicalin for ocular drug delivery system in vitro and in vivo. Drug Dev. Ind. Pharm. 37 (2011), 475–481, 10.3109/03639045.2010.522193.
86. [86] Liu, R., Liu, Z., Zhang, C., Zhang, B., Nanostructured lipid carriers as novel ophthalmic delivery system for mangiferin: improving in vivo ocular bioavailability. J. Pharm. Sci. 101 (2012), 3833–3844, 10.1002/jps.23251.
87. [87] Zhang, W., Li, X., Ye, T., Chen, F., Sun, X., Kong, J., et al. Design, characterization, and in vitro cellular inhibition and uptake of optimized genistein-loaded NLC for the prevention of posterior capsular opacification using response surface methodology. Int. J. Pharm. 454 (2013), 354–366, 10.1016/j.ijpharm.2013.07.032.
88. [88] Zhang, W., Liu, J., Zhang, Q., Li, X., Yu, S., Yang, X., et al. Enhanced cellular uptake and anti-proliferating effect of chitosan hydrochlorides modified genistein loaded NLC on human lens epithelial cells. Int. J. Pharm. 471 (2014), 118–126, 10.1016/j.ijpharm.2014.05.030.
89. [89] Hao, J., Wang, X., Bi, Y., Teng, Y., Wang, J., Li, F., et al. Fabrication of a composite system combining solid lipid nanoparticles and thermosensitive hydrogel for challenging ophthalmic drug delivery. Colloids Surf. B Biointerf. 114 (2014), 111–120, 10.1016/j.colsurfb.2013.09.059.
90. [90] Strettoi, E., Gargini, C., Novelli, E., Sala, G., Piano, I., Gasco, P., et al. Inhibition of ceramide biosynthesis preserves photoreceptor structure and function in a mouse model of retinitis pigmentosa. Proc. Natl. Acad. Sci. USA 107 (2010), 18706–18711, 10.1073/pnas.1007644107.
91. [91] Hauswirth, W.W., Beaufrere, L., Ocular gene therapy: quo vadis?. Invest. Ophthalmol. Vis. Sci. 41 (2000), 2821–2826.
92. [92] Apaolaza, P.S., Delgado, D., Del Pozo-Rodríguez, A., Gascón, A.R., Solinís, M.Á., A novel gene therapy vector based on hyaluronic acid and solid lipid nanoparticles for ocular diseases. Int. J. Pharm. 465 (2014), 413–426, 10.1016/j.ijpharm.2014.02.038.
93. [93] Wang, Y., Rajala, A., Rajala, R., Lipid nanoparticles for ocular gene delivery. J. Funct. Biomater. 6 (2015), 379–394, 10.3390/jfb6020379.
94. [94] Mukherjee, S., Rai, S., Thakur, R., Solid lipid nanoparticles: a modern formulation approach in drug delivery system. Indian J. Pharm. Sci. 71 (2009), 349–358.
95. [95] del Pozo-Rodríguez, A., Delgado, D., Solinís, M.A., Gascón, A.R., Pedraz, J.L., Solid lipid nanoparticles for retinal gene therapy: transfection and intracellular trafficking in RPE cells. Int. J. Pharm. 360 (2008), 177–183, 10.1016/j.ijpharm.2008.04.023.
96. [96] Delgado, D., Del Pozo-Rodríguez, A., Solinís, M.A., Rodríguez-Gascón, A., Understanding the mechanism of protamine in solid lipid nanoparticle-based lipofection: the importance of the entry pathway. Eur. J. Pharm. Biopharm. 79 (2011), 495–502, 10.1016/j.ejpb.2011.06.005.